Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials

BACKGROUND: High sustained virological response at 12 weeks after end of treatment (SVR12) with 12 weeks of simeprevir and sofosbuvir±ribavirin (SMV+SOF±RBV) has been demonstrated in hepatitis C virus genotype 1 (HCV-1) but is based on limited data. Therefore, we performed a meta-analysis of availab...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMJ Open Gastroenterol
Autori principali: Yee, Brittany E, Nguyen, Nghia H, Jin, Minjuan, Lutchman, Glen, Lim, Joseph K, Nguyen, Mindie H
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2016
Soggetti:
Meta Analysis
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4780041/
https://ncbi.nlm.nih.gov/pubmed/26966547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjgast-2015-000056
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi